In this study, due to the side effect profiles and low efficacy of currently used inhibitors, novel benzimidazole-oxadiazole derivatives (6a-6e, 7a-7e) were synthesized as dual inhibitors of alpha-GLY and AR. Their structures were elucidated using 13C-NMR and 1H-NMR techniques. Their binding properties were investigated by molecular docking studies, and their ADME properties were screened in silico. AR and alpha-GLY inhibitory effects of the synthesized compounds were examined. The compounds were observed to exhibit partially similar inhibitory effects to the reference drug epalrestate (IC 50: 0.78 nM; K I: 0.74 +/- 0.0 nM) on AR inhibition. Among them, compounds 6a, 6b, and 6c showed the highest activity with K I values of 8.6 +/- 0.4, 3.5 +/- 0.3 and 6.3 +/- 0.5 nM, respectively. Compounds 6a and 7e were found to have higher inhibitory activity against the alpha-GLY enzyme than the reference drug Acarbose (IC 50: 128.4 & micro;M; K I: 96.2 +/- 5.7 & micro;M) with K I values of 5.8 +/- 0.4 and 7.9 +/- 0.8 & micro;M, respectively. Overall, the newly synthesized compounds demonstrated pronounced AR inhibitory activity and notable alpha-GLY inhibition. Nevertheless, further pharmacological and toxicity evaluations are required to confirm their therapeutic potential. Among the tested molecules, compounds 6a and 7e may therefore be considered potential candidates for further investigation as anti-diabetic agents.